



## Supplemental Figures

### Supplemental Figure 1.



Chen, F., et al., *Clinical Implications of Genetic Variation in Carboxylesterase Drug Metabolism*. Vol. 14. 2018. 131-142.


## Supplemental Figure 2.



Lang, D., C. Freudenberger, and C. Weinz, *In Vitro Metabolism of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Liver Microsomes and Hepatocytes of Rats, Dogs, and Humans*. Drug Metabolism and Disposition, 2009. 37(5): p. 1046

### Supplemental Figure 3.


#### Apixaban metabolism



Modified from

Wang, L. et al Sulfation of o-demethyl apixaban: enzyme identification and species comparison. *Drug Metabolism Disposition*. 2009 Apr;37(4):802-8.

## Supplemental Figure 4.



Parasrampur, D.A. and K.E. Truitt, *Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa*. Clin Pharmacokinet, 2016. **55**(6): p. 641-55.